2020-241A - Laserfiche WebLink

Home Browse Search

2.2 ESI's Rieht of Equitable Adjustment. If Client makes material changes to its Formulary or benefit design that negatively impact ESI's ability to control inflation relative to Client's Formulary drug mix, then Client acknowledges that ESI or Administrator reserves the right in ESI's discretion to make an equitable adjustment to the Client Inflation Payment. 2.3 The ESI IP Program, and the underlying economics, is separate and apart from rebates and manufacturer administrative fees, and the amounts described above in this Section E will be paid to Client in addition to any rebate payments to which Client is entitled pursuant to the terms of this Agreement. Client will not be entitled to receive any amounts related to drug price inflation or a related guarantee other than as set forth above in this Section E of this Exhibit A (Client Application). 2.4 No payments will be made to Client unless Client has executed this Agreement. F. EXECUTION BY CLIENT Client hereby represents and warrants that the information contained in Section A of this Client Application is true and correct in all respects and Client hereby agrees to the specific terms, conditions and financial arrangements set out in Sections B, C, D and E of this Client Application. Client agrees that if any information in Section A changes, Client will give Administrator prompt notice of such changes. Furthermore, Client understands that this Client Application(Exhibit A is a part of the Administrative Services Agreement between Client and Administrator to which it is attached and incorporated into by reference and that Client is bound by all terms and conditions of such Administrative Services Agreement. All capitalized terms used in this Client Application but not specifically defined herein shall have the meanings given to such terms in the Administrative Services Agreement to which this Client Application is attached and made a part of.